Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SR11237 is a Pan retinoid X receptor (RXR) agonist. SR11237 causes RXR/RXR homodimers to form and transactivate a reporter gene containing a RXR-response element.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 77.00 | |
5 mg | In stock | $ 189.00 | |
10 mg | In stock | $ 287.00 | |
25 mg | In stock | $ 578.00 | |
50 mg | In stock | $ 833.00 | |
100 mg | In stock | $ 1,150.00 | |
500 mg | In stock | $ 2,290.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 239.00 |
Description | SR11237 is a Pan retinoid X receptor (RXR) agonist. SR11237 causes RXR/RXR homodimers to form and transactivate a reporter gene containing a RXR-response element. |
In vitro | SR11237 is effective at transactivating a chloramphenicol acetyltransferase reporter gene through RXRs but not retinoic acid receptors in COS-1 cells[2]. |
In vivo | In Sprague-Dawley rats, SR11237 (BMS-649) (25 mg/kg; i.p.) Caused disturbed ossification and bone morphology in rats, including premature growth plate closure and infiltration of ossified tissue through the central epiphysis[3]. |
Synonyms | SR 11237 |
Molecular Weight | 380.48 |
Formula | C24H28O4 |
CAS No. | 146670-40-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 4 mg/mL (10.51 mM), ultrasonic and warming and heat to 60°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SR11237 146670-40-8 Metabolism Others RAR/RXR Retinoid X receptors bone BMS 649 transactivate BMS649 Retinoic acid receptors reporter ossification RAR/RXR inhibit Inhibitor RXR/RXR BMS-649 homodimers SR-11237 gene SR 11237 inhibitor